Staff

TOP 5 publications:

1. Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism.Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
2. Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany.Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
3. Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.JAMA Psychiatry. 2026 83(5):448-460. Epub 2026 Mar 18.
4. Mertens L, Betzler F, Brand M, Evens R, Jungaberle A, Jungaberle H, Kärtner L, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Harder H, Kirchen N, Kulakova E, Kunz LC, Meijer A, Rohrmoser B, Wellek S, Berger M, Koslowski M, Gründer G. Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.Psychother Psychosom. 2026 May 27. [Epub ahead of print]:1-28.
5. Gründer G, Mertens L, Spangemacher M, Meyer-Lindenberg A, Jungaberle H. Psychedelics: The pathway to implementation in the European healthcare systems.Eur Neuropsychopharmacol. 2025 102:41-48. Epub 2025 Dec 2.